Development of anthracycline-induced dilated cardiomyopathy due to mutation on LMNA gene in a breast cancer patient: a case report
Abstract Background Anthracyclines are highly effective anticancer medication prescribed for the treatment of breast cancer. Nevertheless, the use of anthracyclines as chemotherapeutic agents involves a risk for development of cardiac toxicity which may cause restrictive and dilated cardiomyopathy....
Main Authors: | Jock Chichaco Kuruc, Armando A. Durant-Archibold, Jorge Motta, K. S. Rao, Barry Trachtenberg, Carlos Ramos, Hongyu Wang, David Gorenstein, Fredrik Vannberg, King Jordan |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-07-01
|
Series: | BMC Cardiovascular Disorders |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12872-019-1155-7 |
Similar Items
-
Novel linkage of LMNA Single Nucleotide Polymorphism with Dilated Cardiomyopathy in an Indian case study
by: Avinanda Banerjee, et al.
Published: (2015-06-01) -
Roles of ERK1/2 signaling in LMNA-cardiomyopathy
by: Chatzifrangkeskou, Maria
Published: (2016) -
Activation of sarcolipin expression and altered calcium cycling in LMNA cardiomyopathy
by: Blanca Morales Rodriguez, et al.
Published: (2020-07-01) -
Investigating <i>LMNA</i>-Related Dilated Cardiomyopathy Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
by: Yuval Shemer, et al.
Published: (2021-07-01) -
Deletion of entire LMNA gene as a cause of cardiomyopathy
by: Allison L. Cirino, MS, et al.
Published: (2020-07-01)